Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex PLC - Notification of interim results

4 September 2012 - Cyprotex (AIM:CRX), the specialist preclinical contract research organisation (CRO), will be publishing its interim results for the six months ended 30 June 2012 on Thursday 6 September 2012.

Tony Baxter, Chief Executive Officer, and John Dootson, Chief Financial Officer, will present the results to analysts at 9.30am at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London,
WC2A 1PB.


Enquiries:

Cyprotex PLC  Tel:  +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
 
www.cyprotex.com


Singer Capital Markets Limited (Nomad and broker to Cyprotex) Tel:  +44 (0)20 7496 3000
Shaun Dobson
shaun.dobson@singercm.com

Claes Spang
claes.spang@singercm.com 
www.singercm.com


FTI Consulting Tel:  +44 (0) 20 7831 3113
Simon Conway
Mo Noonan
cyprotex@fticonsulting.com
      
www.fticonsulting.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close